DrugPatentWatch Database Preview
Details for Patent: 9,738,625
» See Plans and Pricing
Which drugs does patent 9,738,625 protect, and when does it expire?
Patent 9,738,625 protects IDHIFA and is included in one NDA.
This patent has thirty-two patent family members in twenty countries.
Summary for Patent: 9,738,625
| Title: | Therapeutically active compounds and their methods of use |
| Abstract: | Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes. |
| Inventor(s): | Agresta; Samuel V. (Lexington, MA), Gu; Chong-Hui (Waban, MA), Schenkein; David (Boston, MA), Yang; Hua (Acton, MA), Guo; Liting (Suzhou, CN), Tang; Zhen (Suzhou, CN), Wang; Jianming (Suzhou, CN), Zhang; Yanfeng (Suzhou, CN), Zhou; Yan (Suzhou, CN) |
| Assignee: | Agios Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 14/909,451 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 9,738,625
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,738,625
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| PCT/CN2013/081170 | Aug 9, 2013 | |
| PCT Information | |||
| PCT Filed | August 01, 2014 | PCT Application Number: | PCT/US2014/049469 |
| PCT Publication Date: | February 05, 2015 | PCT Publication Number: | WO2015/017821 |
International Family Members for US Patent 9,738,625
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 097237 | Start Trial | |||
| Australia | 2014295938 | Start Trial | |||
| Australia | 2018247242 | Start Trial | |||
| Brazil | 112016002287 | Start Trial | |||
| Canada | 2919382 | Start Trial | |||
| Chile | 2016000263 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
